Eyegate Pharmaceuticals Inc fka EYEG

[jmoney360]

$EYEG On April 17, 2018, the Company completed its previously announced public offering of common stock, Series C Preferred Stock and warrants, with total gross proceeds of $11.25 million (the “Offering”), as disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 13, 2018. The net proceeds to the Company from the Offering, after deducting the placement agent fees and the Company’s estimated offering expenses, will be approximately $10.1 million.